These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 16309461)

  • 1. Inhibition of SOS Response by Nitric Oxide Donors in
    Crane JK; Burke SR; Alvarado CL
    Front Cell Infect Microbiol; 2021; 11():798136. PubMed ID: 35004358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of
    Rhayat L; Maresca M; Nicoletti C; Perrier J; Brinch KS; Christian S; Devillard E; Eckhardt E
    Front Immunol; 2019; 10():564. PubMed ID: 30984172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.
    Liévin-Le Moal V; Servin AL
    Microbiol Mol Biol Rev; 2013 Sep; 77(3):380-439. PubMed ID: 24006470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations that impact the enteropathogenic Escherichia coli Cpx envelope stress response attenuate virulence in Galleria mellonella.
    Leuko S; Raivio TL
    Infect Immun; 2012 Sep; 80(9):3077-85. PubMed ID: 22710873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The enteropathogenic E. coli (EPEC) Tir effector inhibits NF-κB activity by targeting TNFα receptor-associated factors.
    Ruchaud-Sparagano MH; Mühlen S; Dean P; Kenny B
    PLoS Pathog; 2011 Dec; 7(12):e1002414. PubMed ID: 22144899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-κB activation.
    Royan SV; Jones RM; Koutsouris A; Roxas JL; Falzari K; Weflen AW; Kim A; Bellmeyer A; Turner JR; Neish AS; Rhee KJ; Viswanathan VK; Hecht GA
    Mol Microbiol; 2010 Dec; 78(5):1232-45. PubMed ID: 21091507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The enteropathogenic E. coli effector EspF targets and disrupts the nucleolus by a process regulated by mitochondrial dysfunction.
    Dean P; Scott JA; Knox AA; Quitard S; Watkins NJ; Kenny B
    PLoS Pathog; 2010 Jun; 6(6):e1000961. PubMed ID: 20585567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The type III secretion effector NleE inhibits NF-kappaB activation.
    Nadler C; Baruch K; Kobi S; Mills E; Haviv G; Farago M; Alkalay I; Bartfeld S; Meyer TF; Ben-Neriah Y; Rosenshine I
    PLoS Pathog; 2010 Jan; 6(1):e1000743. PubMed ID: 20126447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flagellin-dependent and -independent inflammatory responses following infection by enteropathogenic Escherichia coli and Citrobacter rodentium.
    Khan MA; Bouzari S; Ma C; Rosenberger CM; Bergstrom KS; Gibson DL; Steiner TS; Vallance BA
    Infect Immun; 2008 Apr; 76(4):1410-22. PubMed ID: 18227166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of intestinal goblet cell function during infection by an attaching and effacing bacterial pathogen.
    Bergstrom KS; Guttman JA; Rumi M; Ma C; Bouzari S; Khan MA; Gibson DL; Vogl AW; Vallance BA
    Infect Immun; 2008 Feb; 76(2):796-811. PubMed ID: 17984203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enteropathogenic Escherichia coli (EPEC) inactivate innate immune responses prior to compromising epithelial barrier function.
    Ruchaud-Sparagano MH; Maresca M; Kenny B
    Cell Microbiol; 2007 Aug; 9(8):1909-21. PubMed ID: 17388785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOS regulation of the type III secretion system of enteropathogenic Escherichia coli.
    Mellies JL; Haack KR; Galligan DC
    J Bacteriol; 2007 Apr; 189(7):2863-72. PubMed ID: 17237173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota.
    Liévin-Le Moal V; Servin AL
    Clin Microbiol Rev; 2006 Apr; 19(2):315-37. PubMed ID: 16614252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enteropathogenic Escherichia coli (EPEC) effector-mediated suppression of antimicrobial nitric oxide production in a small intestinal epithelial model system.
    Maresca M; Miller D; Quitard S; Dean P; Kenny B
    Cell Microbiol; 2005 Dec; 7(12):1749-62. PubMed ID: 16309461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of uropathogenic Escherichia coli and proinflammatory cytokines on the inducible nitric oxide synthase response in human kidney epithelial cells.
    Poljakovic M; Svensson L; Persson K
    J Urol; 2005 Mar; 173(3):1000-3. PubMed ID: 15711365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells.
    Oh JH; Lee TJ; Park JW; Kwon TK
    Eur J Pharmacol; 2008 Dec; 599(1-3):11-7. PubMed ID: 18838070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orazipone inhibits activation of inflammatory transcription factors nuclear factor-kappa B and signal transducer and activator of transcription 1 and decreases inducible nitric-oxide synthase expression and nitric oxide production in response to inflammatory stimuli.
    Sareila O; Hämäläinen M; Nissinen E; Kankaanranta H; Moilanen E
    J Pharmacol Exp Ther; 2008 Feb; 324(2):858-66. PubMed ID: 18039960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of EPEC type III effector molecules.
    Kenny B
    Int J Med Microbiol; 2002 Feb; 291(6-7):469-77. PubMed ID: 11890546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of nitric oxide in acute lung injury.
    Mehta S
    Vascul Pharmacol; 2005 Dec; 43(6):390-403. PubMed ID: 16256443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.